

Company Announcement  
No. 19 / 2015

## Zealand announces total number of shares and voting rights in the company as of 30 April 2015

Copenhagen, 30 April 2015 - Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand"), in accordance with Section 6 of the Danish Statutory Order on Issuers' Disclosure Obligations, is required to announce the total share capital and number of voting rights in the company at the end of a month where changes therein have occurred.

With reference to Corporate Announcement no. 14/2015 dated 11 April 2015, the table below provides the total number of shares and voting rights in Zealand as of 30 April 2015.

	Number of shares (nominal value DKK 1)	Nominal value (DKK)	Number of votes
Shares	23,420,100	23,420,100	23,420,100



### For further information, please contact:

Hanne Leth Hillman, Senior Vice President for Investor Relations & Communications  
Tel: +45 50 60 36 89, email: [lh@zealandpharma.com](mailto:lh@zealandpharma.com)

### About Zealand Pharma

Zealand Pharma A/S ("Zealand") (Nasdaq Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand has leading expertise in the discovery, design and development of novel peptide medicines and possesses in-house competences in clinical trial design and management with a therapeutic focus on metabolic diseases and acute care indications. The company is advancing a pipeline of novel wholly-owned medicines alongside a partnered product and development portfolio.

Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes, is marketed globally (ex-US) as Lyxumia® and in Phase III development as a single-injection combination with Lantus® (LixiLan), both under a global license agreement with Sanofi. US regulatory submission of Lyxumia® is planned for Q3 2015 and US/EU regulatory submissions for LixiLan in Q4 2015.

Zealand's wholly-owned products include danegaptide (prevention of Ischemic Reperfusion Injury) in Phase II and the stable glucagon product, ZP4207 (treatment of severe hypoglycemia) in Phase I as well as several preclinical peptide therapeutics. Partnering represents an important component of strategy to leverage in-house expertise, share development risk in large clinical trials, provide funding and commercialize the company's products. Zealand currently has global license agreements and partnerships with Sanofi, Helsinn Healthcare, Boehringer Ingelheim and Eli Lilly.

For further information: [www.zealandpharma.com](http://www.zealandpharma.com)

Follow us on Twitter @ZealandPharma